Login
$CGON
$84.48 -$0.30 (0.35%) After hours

$CGON 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

06 Nov 2026 8-K: Results of Operations and Financial Condition

DALLAS, Texas, November 6, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

06 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 4, 2026, CG Oncology, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 7, 2026, the record date for the Annual Meeting, 88,009,980 shares of common stock were outstanding and e...

26 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 20, 2026, CG Oncology, Inc. (the “Company”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026. The Company thanks Mr. Belle...

08 May 2026 8-K: Results of Operations and Financial Condition

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026

13 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (this “Agreement”) is made by and between CG Oncology, Inc. (the “Company”), and Jim DeTore (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), effective as...

27 Feb 2026 8-K: Results of Operations and Financial Condition

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026

13 Jan 2026 8-K: Other Events

We have acted as counsel to CG Oncology, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having ...

09 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, inclu...

26 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 22, 2025, the Board of Directors (the “Board”) of CG Oncology, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Christina Rossi to the Company’s Board,...

14 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 10, 2025, Robert Lapetina, interim principal financial and accounting officer of CG Oncology, Inc. (the “Company”) delivered to the Company a notice of resignation from his position as interim principal financial and accounti...

14 Nov 2025 8-K: Results of Operations and Financial Condition

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

09 Sep 2025 8-K: Regulation FD Disclosure

Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, inclu...

05 Sep 2025 8-K: Regulation FD Disclosure; Other Events

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

08 Aug 2025 8-K: Results of Operations and Financial Condition

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in

11 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On July 7, 2025, Corleen Roche, Chief Financial Officer of CG Oncology, Inc. (the “Company”) delivered to the Company a 30-day notice of resignation from her position as Chief Financial Officer of the Company. Ms. Roche’s resignation is ...

06 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2025, CG Oncology, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 8, 2025, the record date for the Annual Meeting, 76,221,857 shares of common stock were outstanding and e...

13 May 2025 8-K: Results of Operations and Financial Condition

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -

28 Apr 2025 8-K: Regulation FD Disclosure; Other Events

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support